Journal of Cardiovascular Pharmacology 2007-10-01

Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease.

R M A van de Wal, P van der Harst, L J Wagenaar, S Wassmann, W J Morshuis, G Nickenig, H Buikema, H W M Plokker, D J van Veldhuisen, W H van Gilst, A A Voors

Index: J. Cardiovasc. Pharmacol. 50(4) , 372-9, (2007)

Full Text: HTML

Abstract

Several animal studies suggested that the angiotensin II type 2 (AT2) receptor subtype mediates vasodilation, yet the results in human arteries are less well described and more inconsistent. Therefore, we evaluated the role of the AT2 receptor stimulation on the vasotonus of human internal mammary arteries.Internal mammary arteries were obtained from 50 patients undergoing coronary bypass surgery. The expression of angiotensin II type 1 (AT1) receptor and AT2 receptor mRNA was determined by using real-time polymerase chain reaction. In addition, angiotensin II and CGP42112A concentration-response curves (concentration range: 10(-10) M to 10(-6) M) were constructed in absence or presence of candesartan (10(-5) M) and/or the AT2 receptor-antagonist PD-123319 (10(-6) M) and/or the alpha receptor antagonist phentolamine.Both AT1 and AT2 receptor protein and mRNA were detected, and higher AT2 receptor mRNA expression levels were associated with increased contractile response to angiotensin II. Angiotensin II caused vasoconstriction up to 41.1 +/- 6.5% of the maximal response to phenylephrine, and PD123319 significantly reduced this response (28.6 +/- 9.6%, P < 0.001). Candesartan completely blocked the angiotensin II-mediated response (1.4 +/- 3.1%, P < 0.001 versus control), and additional blockade of the AT2 receptor with PD123319 did not change this effect (1.8 +/- 5.1%). Phentolamine (10(-5) M) caused attenuation and rightward shift of the angiotensin II concentration response curves. The AT2 receptor agonist CGP42112A did not induce a significant response.Although AT2 receptor mRNA is present in human internal mammary arteries, AT2 receptor stimulation does not mediate vasodilation in these arteries.


Related Compounds

Related Articles:

Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.

2011-01-01

[BMC Cancer 11 , 274, (2011)]

Update on the angiotensin AT(2) receptor.

2013-02-01

[Curr. Hypertens. Rep. 15(1) , 25-30, (2013)]

Angiotensin III modulates the nociceptive control mediated by the periaqueductal gray matter

2009-12-15

[Neuroscience 164(3) , 1263-73, (2009)]

Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats.

2009-03-01

[Am. J. Physiol. Heart Circ. Physiol. 296(3) , H745-55, (2009)]

Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats.

2012-06-01

[J. Hypertens. 30(6) , 1176-84, (2012)]

More Articles...